Sentences with phrase «preclinical models with»

It is currently being evaluated for safety and efficacy in preclinical models with a Phase I trial expected to begin in 2019.

Dr. Norman Karin, a biologist at PNNL, has identified a lipid growth factor called lysophosphatidic acid (LPA) that promotes bone healing in preclinical models with no apparent toxicity.

Not exact matches

In preclinical studies using cell models that mimicked liver cells of patients with the rare disease Friedreich's ataxia (FA), a widely used cholesterol - lowering drug increased a precursor of HDL (high - density lipoprotein), the «good cholesterol,» according to new research published in PLOS ONE from the Perelman School of Medicine at the University of Pennsylvania.

Furthermore, the team found that ONA inhibited the pro-tumor functions of myeloid derived suppressor cells (MDSC), which are closely associated with the suppression of the anti-tumor immune response of host lymphocytes, by using preclinical sarcoma model.

In multiple preclinical models, OMP - 54F28 (FZD8 - Fc) has shown its effectiveness in reducing CSC populations, leading to associated anti-tumor activity, either as a single agent or when combined with chemotherapy.

Currently, Deng's laboratory is conducting additional preclinical studies using the human - derived stem cells from Down syndrome patients and mouse models to determine whether cellular and behavioral abnormalities can be improved with minocycline therapy and other candidate drugs.

Solving these problems in preclinical models is much more cost effective, but requires a multidisciplinary team that includes formulation experts, polymer scientists, and biologists who can interface with diverse scientists who don't normally talk to one another.

With this new understanding of how Del - 1 can inhibit periodontal bone loss — both by reducing inflammation and by restraining the activity of osteoclasts that resorb bone tissue — the researchers tested it, in a preclinical model of periodontitis observing that Del - 1 significantly reduced inflammation and tissue damage and that there was significantly less bone loss.

Combining their strategy with an existing immunotherapy treatment that works by releasing the «brakes» on immune cells, they found they could shrink melanoma tumors, and prolong survival in preclinical models for melanoma.

The other study — Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma — published March 30, shows how drugs targeting PI3K and MAPK could represent promising candidates for glioblastoma therapy.

«The model for preclinical studies to predict with great accuracy which drugs would work in the clinic was developed a decade ago,» says Dr. Chesi.

Using all the existing data that was available, Andrechek, along with MSU doctoral student Daniel Hollern, analyzed 1,172 mouse mammary tumor samples from 26 different preclinical models and was able to compile one of the largest databases to show which strains of mice were best suited to study a particular type of human breast cancer.

Researchers suggested that other classes of inhibitors be tested in combination with ERK5 inhibitors in human colorectal cancer cells in preclinical mouse models before any patient trial can begin.

Currently, Doody is testing in preclinical models whether combining this agent with other, known rheumatoid arthritis treatments results in more efficacious therapies.

According to the authors of the study, in future researches it will be necessary to know about the action mechanism of the new products - highly selective and with low cell toxicity on in vitro tests - and broaden preclinical studies with laboratory animal models.

«Stem cell - based therapy for targeting skin - to - brain cancer: Stem cells loaded with oncolytic viruses show promising results in preclinical models for targeting skin cancer metastases in the brain.»

Our scientists engage with you in the design and execution of your preclinical drug development program using our AAALAC approved animal facilities, proprietary animal models, and extensive capabilities.

She has identified novel immune - modulating activities associated with targeted cancer drugs in preclinical models, and developed synergistic immunotherapy combinations.

A major asset of the OMC platform is the tight integration of preclinical scientists with physicians, who work side by side to comparatively assess pathogenic, diagnostic and therapeutic issues raised in patients with the mouse model counterpart.

W. Bogers: PhD in immunology and 20 years of experience with NHP models for the preclinical evaluation of HIV vaccine candidates as well as testing antivirals.

Other humanized mice have no spontaneous phenotype and can be combined with either genetic spontaneous or inducible models of chronic inflammatory diseases yielding preclinical efficacy evaluation platforms for Rheumatoid Arthritis, Intestinal Inflammation, Psoriasis and Multiple Sclerosis.

iTeos is now developing EOS200271 which is a synthetic, small molecule inhibitor of indoleamine 2,3 - dioxygenase (IDO1), which has demonstrated the same anti-tumour activity in multiple preclinical tumour models in combination with immune checkpoint inhibitors as competitors, but also has demonstrated superior brain penetration.

She has collaborated with interdisciplinary groups to investigate how nutritional supplements (phytochemicals and omega - 6 and omega - 3 fatty acids) affect menopause - associated metabolic disturbances and breast cancer in preclinical models (cell and mouse) and clinical settings.

Having a strong R&D department with great experience and expertise in drug development, animal model and assay development and preclinical efficacy evaluation, the contribution of Biomedcode has been greatly valued by our partners, as documented by our participation in several collaborative research projects.

This included 7 genes with renal function which have never been analysed in a preclinical model before.

Together, this translational program is developed within the National Cancer and Cognition Platform (CNO / Ligue Nationale contre le cancer), with the aim to collaborate in a structured way with French oncology groups, research teams as well as pharmaceutical industry, by providing preclinical models and guidance on standard operating procedures for ancillary or future studies in identified population at risk.

EOS200271 has demonstrated anti-tumor activity in multiple preclinical tumor models in monotherapy and in combination with immune checkpoint inhibitors.

M1: Passive transfer studies in preclinical model performed; Report on protection by passive therapy with human immune IgG

Hu H, Gomero E, Bonten E, Gray JT Allay J, Wu Y, Wu J, Calabrese C, Nienhuis A, d'Azzo A. Preclinical dose - finding study with a liver - tropic, recombinant AAV - 2 / 8 vector in the mouse model of galactosialidosis.

Both recent experience with immunotherapy for clearance of Aβ in AD, and their own (and Prothena's) experience with AS - clearing immunotherapies in animal models, indicate that in order to be effective as disease - modifying agents when administered alone, therapies that remove proteinaceous aggregates from the brain must be initiated in the early clinical or even preclinical stages of the disease, before the burden of other forms of aging damage becomes entrenched.

AFF 1: Preclinical Efficacy Data AFF 1 was then tested for preclinical efficacy in two models of human synucleinopathy: mThy1 - AS mice, and also PDGF - AS mice expressing WT human AS under the PDGF - β promoter — a model with closer neuropathological and metabolic resemblance to LPreclinical Efficacy Data AFF 1 was then tested for preclinical efficacy in two models of human synucleinopathy: mThy1 - AS mice, and also PDGF - AS mice expressing WT human AS under the PDGF - β promoter — a model with closer neuropathological and metabolic resemblance to Lpreclinical efficacy in two models of human synucleinopathy: mThy1 - AS mice, and also PDGF - AS mice expressing WT human AS under the PDGF - β promoter — a model with closer neuropathological and metabolic resemblance to LBD than PD.

The phenotyping department of PHENOMIN - ICS is advancing a technical platform for functional characterization of preclinical models of human diseases with respect to both genetic understanding of pathophysiological mechanisms and the assessment of drug therapies.

We have recently identified which cells are uniquely responsible for the metastasis formation in OSCC, and they exhibit the following characteristics: i) they are exclusive in their ability to generate metastases; ii) they express the fatty acid translocase CD36, and express a unique lipid metabolic signature; iii) they directly link metastasis predisposition to dietary fat content; iv) they increase their metastatic initiation potency when treated with palmitic acid; v) they are highly sensitive to CD36 inhibition, which almost completely abolishes their metastatic potential in preclinical models (Pascual et al., Nature 2016).

With our anti-TIGIT antibody program, we saw anti-tumor efficacy and reactivation of T - cells in preclinical models which is encouraging for the potential of this product as a monotherapy

PHILADELPHIA — In preclinical studies using cell models that mimicked liver cells of patients with the rare disease Friedreich's ataxia (FA), a widely used cholesterol - lowering drug increased a precursor of HDL (high - density lipoprotein), the «good cholesterol,» according to new research published in PLOS One from the Perelman School of Medicine at the University of Pennsylvania.

Standardized exploration of physiological functions, scientific and ethical considerations, study design, analysis and data management, alternative imaging method tests / Preclinical approaches with mouse models, a first step toward the man, interest and limits

and affinity of antibody ACI - 5400 were characterized by a panel of methods: (i) measuring the selectivity for a specific phospho - Tau epitope known to be associated with tauopathy, (ii) performing a combination of peptide and protein binding assays, (iii) staining of brain sections from mouse preclinical tauopathy models and from human subjects representing six different tauopathies, and (iv) evaluating the selective binding to pathological epitopes on extracts from tauopathy brains in non-denaturing sandwich assays.

The goal of this Center of Excellence is to better define thrombus development in patients with cancer, test the efficacy of novel therapies, develop new preclinical models, and create and expand biorepositories to provide a valuable resource to researchers across Cleveland Clinic.

The lab used MRS in a preclinical study of SAPAP3 knockout mice — which model aspects of human obsessive compulsive and related disorders (OCRD)-- to determine whether these mice exhibit neurochemical abnormalities found in humans with OCRD.

«Using our preclinical model, we will determine what existing chemotherapies can be combined with this novel drug type to produce the best therapeutic effects,» he said.

Here we report the development and preclinical characterization of a novel CD123 - targeting ADC, IMGN632, which utilizes a highly potent DNA - alkylating payload, resulting in an ADC with robust preclinical activity in multiple models of AML.

His research group actively collaborates with several pharmaceutical companies to provide valuable preclinical data in animal models for their targeted drugs.

At Sanofi I worked in a preclinical group, working with a team to develop a novel mouse model.

However, ADCs that use derivatives of calicheamicin, which promotes double - stranded DNA breaks, such as GO and inotuzumab ozogamicin, 40,41 have limited activity in cells with high multidrug resistance protein activity, a phenotype found in a significant fraction of AML patients.42 Another ADC, SGN - CD123A, comprising an engineered form of the CD123 - targeting 7G3 antibody conjugated to a synthetic pyrrolobenzodiazepine dimer, which acts via DNA crosslinking, has entered clinical trials after showing robust activity in preclinical models of AML, including those with multidrug resistance.33